[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584210":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":50,"collaborators":18,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":18,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Systane COMPLETE","EXPERIMENTAL","The experimental group will receive Systane COMPLETE for one month before undergoing the cataract surgery and receive for one month since one week after the surgery.",[13],"Drug: Systane Complete",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","The control group will enrolled people who meet the same age and same dry eye syndrome criteria as the experimental group. The control group will not received any intervention.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Systane Complete","Systane COMPLETE is an artificial tears that contain nano-emulsion of mineral oil and phospholipids.",[9],[26],{"name":27,"affiliation":5,"role":28},"Chiun Ho Hou, Ph.D","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","+88623123456","262131","chiunhohou@gmail.com",[36],{"facility":5,"status":37,"city":38,"state":18,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Taipei","100","Taiwan","TW",{"type":43,"coordinates":44},"Point",[45,46],121.52639,25.05306,{"lat":46,"lon":45},[49],{"name":27,"role":31,"phone":32,"phoneExt":33,"email":34},{"type":51,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100584210","phase-4-optimizing-the-ocular-surface-with-systane-complete-pre--and-post-operatively-in-patients-with-dry-eye-planning-for-cataract-surgery-an-extension-study-of-optimizing-the-ocular-surface-with-systane-complete-in-patients-with-dry-eye-planning-for-cataract-surgery-100584210",false,"NCT06886373","Optimizing the Ocular Surface With Systane COMPLETE Pre- and Post-operatively in Patients With Dry Eye Planning for Cataract Surgery: An Extension Study of Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery","Inclusion Criteria (Experimental group ): Cataract patients who participated in the \"Optimizing the Ocular Surface with Systane COMPLETE in Patients with Dry Eye Planning for Cataract Surgery\" trial (Research Ethics Committee Approval Number: 202311109MIPD) and did not withdraw from the trial midway.\n\nExclusion Criteria (Experimental group ): Patients unwilling to participate in this trial after surgery.\n\nInclusion Criteria(Control group):\n\n* Cataract patients aged between 20 and 85 years.\n* Patients with normal cognitive function who are able to complete the dry eye questionnaire (with - responses recorded by the research team) and are willing to undergo phacoemulsification and intraocular lens implantation under topical anesthesia.\n\nExclusion Criteria (Control group):\n\n* Unable to answer the questions in the dry eye survey.\n* Ocular trauma or ocular surgery in the planned surgical eye, active ocular infection, and obvious abnormalities in ocular surface or eyelid margins other than MGD cause decreased visual acuity other than cataracts.\n* Dry eye signs: Corneal Fluorescein Staining CFS (+) to exclude any corneal abnormalities or epithelial defect.\n* Systemic drug use, including tetracycline derivatives, antihistamines, and isotretinoin.\n* Using dry eye medication at screening stage.","ALL","20 Years","85 Years",{"count":62,"type":63},140,"ESTIMATED","INTERVENTIONAL",[66],"PHASE4","Compare the corneal astigmatism data before and after the use of Systane COMPLETE to evaluate its impact on predicting changes in postoperative residual astigmatism, as well as the effects of using or not using Systane COMPLETE on preoperative and postoperative Ocular Surface Disease Index (OSDI) scores and Non-Invasive Tear Break-Up Time (NITBUT).",[69],"Ophthalmology",[71,72,73,74,75],"Dry eye","cataract surgery","astigmatism","nano-emulsion","artificial tears","2026-04-21",{"date":78,"type":79},"2026-04-24","ACTUAL",{"date":81,"type":79},"2025-03-25",{"date":83,"type":63},"2027-12-31",{"name":5,"class":6},1]